Regular Article
Release and Degradation of Angiotensin I and Angiotensin II from Angiotensinogen by Neutrophil Serine Proteinases

https://doi.org/10.1006/abbi.2001.2687Get rights and content

Abstract

Cathepsin G, elastase, and proteinase 3 are serine proteinases released by activated neutrophils. Cathepsin G can cleave angiotensinogen to release angiotensin II, but this activity has not been previously reported for elastase or proteinase 3. In this study we show that elastase and proteinase 3 can release angiotensin I from angiotensinogen and release angiotensin II from angiotensin I and angiotensinogen. The relative order of potency in releasing angiotensin II by the three proteinases at equivalent concentrations is cathepsin G > elastase > proteinase 3. When all three proteinases are used together, the release of angiotensin II is greater than the sum of the release when each proteinase is used individually. Cathepsin G and elastase can also degrade angiotensin II, reactions which might be important in regulating the activity of angiotensin II. The release and degradation of angiotensin II by the neutrophil proteinases are reactions which could play a role in the local inflammatory response and wound healing.

References (49)

  • R.A. Santos et al.

    Regul. Pept.

    (2000)
  • A. Reaux et al.

    Trends Endocrinol. Metab.

    (2001)
  • E.A. Kramar et al.

    Brain Res.

    (2001)
  • T.A. Hamilton et al.

    Peptides

    (2001)
  • K.M. Schmidt-Ott et al.

    Regul. Pept.

    (2000)
  • L.B. Klickstein et al.

    J. Biol. Chem.

    (1982)
  • C.F. Reilly et al.

    J. Biol. Chem.

    (1982)
  • V. Witko-Sarsat et al.

    Blood

    (1999)
  • C.M. Kam et al.

    FEBS Lett.

    (1992)
  • Z. Liu et al.

    Cell

    (2000)
  • K. Beatty et al.

    J. Biol. Chem.

    (1980)
  • J. Célérier et al.

    J. Biol. Chem.

    (2000)
  • U. Hilgenfeldt

    Mol. Cell. Endocrinol.

    (1988)
  • K. Yayama et al.

    Life Sci.

    (1995)
  • M.J. Banda et al.

    J. Biol. Chem.

    (1988)
  • J. Potempa et al.

    J. Biol. Chem.

    (1991)
  • F.C. Church et al.

    J. Biol. Chem.

    (1991)
  • L.W. Corbin et al.

    Thromb. Res.

    (1990)
  • M. Hoffman et al.

    Blood

    (1989)
  • D.M. MacIvor et al.

    Blood

    (1999)
  • S. Nakamura et al.

    Kidney Int.

    (2000)
  • D.T. Eitzman et al.

    Blood

    (2000)
  • P.G.W. Gettins et al.

    Serpins: Structure, Function, and Biology

    (1996)
  • D.E. Vaughan

    Am. J. Cardiol.

    (2001)
  • Cited by (43)

    • Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost

      2020, Biochemical Pharmacology
      Citation Excerpt :

      Cathepsin G was reported to be one of the neutrophil-derived serine proteases that is abundantly found in the azurophil granules and known to degrade both Angiotensinogen and Ang I into Ang II [209,210]. So far, NEP can additionally take a part in decreasing the pro-inflammatory, oxidative and pro-fibrotic effects of Ang II by minimizing the release of cathepsin G and consequently, its action on Ang I [211–213]. As NEP was reported to have more catalytic activity than ACE-2 in cleaving Ang I into Ang (1–7), it could also effectively enhance the protective activities associated with Ang (1–7) in the lung [214].

    • Pathophysiological role of osteopontin and angiotensin II in atherosclerosis

      2016, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      Ang II/AT1 signaling pathway leads to an increase in cytokine and chemokine expression, including monocyte chemoattractant protein-1 (MCP-1), IL-6, IL-18, TNF-α and IL-1β [54–57] and so on. Inflammatory cells then have an endogenous RAAS that can produce Ang II, which results in a positive feedback response, perpetuating the inflammatory cycle [58–60]. Mazzolai et al. [53] demonstrated that endogenous Ang II contributes to the modification of stable plaques into a vulnerable lesions for the first time.

    • Myeloblastin

      2013, Handbook of Proteolytic Enzymes
    • Regulation of the renin-angiotensin system (RAS) in BeWo and HTR-8/SVneo trophoblast cell lines

      2012, Placenta
      Citation Excerpt :

      This probably accounts for the greater production of Ang 1-7 by BeWo cells compared to HTR-8/SVneo cells (Fig. 5). An alternative Aogen processing enzyme may also have been present in the culture medium, such as chymase or cathepsin D [29–31]. The latter is less likely, as it is inactive at neutral pH [30].

    • Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease

      2009, American Heart Journal
      Citation Excerpt :

      However, studies have shown that levels of circulating AII return to pretreatment levels in patients receiving long-term ACEI therapy. This process, known as ACE escape, is attributed to alternate pathways for AII, such as those involving cathepsin G and elastase, which may directly convert angiotensinogen to AII, and chymases and cathepsin G, which may convert AI to AII.33-37 On the other hand, ARBs selectively block AII binding at the AT1 receptor without interfering with AII binding to AT2 receptors, thereby, allowing potentially beneficial AT2-mediated effects (vasodilation, inhibition of cell growth, improved endothelial function, and inhibition of collagen deposition).32

    View all citing articles on Scopus
    1

    To whom correspondence and reprint requests should be addressed at Department of Oral Medicine and Diagnostic Sciences (MC 838), 801 South Paulina, Chicago, IL 60612. Fax: 312 355-2688. E-mail: [email protected].

    View full text